Atorvastatin/metformin - Daewoong Pharmaceutical

Drug Profile

Atorvastatin/metformin - Daewoong Pharmaceutical

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fatty acids; Heptanoic acids; Pyrroles; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 12 Dec 2016 Chemical structure information added
  • 01 Aug 2015 Phase-III clinical trials in Dyslipidaemias and Type-2 diabetes mellitus in South Korea (PO) (NCT02947620)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top